stoxline Quote Chart Rank Option Currency Glossary
Olema Pharmaceuticals, Inc. (OLMA)
9.62  -0.03 (-0.31%)    05-30 16:00
Open: 9.71
High: 9.85
Volume: 1,327,040
Pre. Close: 9.65
Low: 9.38
Market Cap: 538(M)
Technical analysis
2024-05-30 4:43:31 PM
Short term     
Mid term     
Targets 6-month :  12.02 1-year :  13.31
Resists First :  10.29 Second :  11.39
Pivot price 9.48
Supports First :  8.51 Second :  7.08
MAs MA(5) :  9.26 MA(20) :  9.8
MA(100) :  11.75 MA(250) :  11.49
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  34.4 D(3) :  26.3
RSI RSI(14): 46.8
52-week High :  17.79 Low :  5.53
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OLMA ] has closed below upper band by 40.7%. Bollinger Bands are 54.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.86 - 9.91 9.91 - 9.94
Low: 9.27 - 9.32 9.32 - 9.36
Close: 9.54 - 9.62 9.62 - 9.69
Company Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Headline News

Mon, 27 May 2024
Jump Financial LLC Makes New $279000 Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World

Fri, 24 May 2024
Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Mon, 20 May 2024
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.6% - MarketBeat

Sat, 11 May 2024
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation - Simply Wall St

Wed, 08 May 2024
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Wed, 08 May 2024
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 56 (M)
Shares Float 28 (M)
Held by Insiders 3.7 (%)
Held by Institutions 95.9 (%)
Shares Short 8,400 (K)
Shares Short P.Month 8,100 (K)
Stock Financials
EPS -2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.25
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -29.9 %
Return on Equity (ttm) -48.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.96
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -4.81
PEG Ratio 0
Price to Book value 2.26
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android